76
|
Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 1988; 21:221-8. [PMID: 3162849 DOI: 10.1007/bf00262774] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The pharmacokinetics and metabolism of doxorubicin (DX) and epirubicin (epiDX) were investigated in eight cancer patients who received 60 mg/m2 of both drugs independently by intravenous (i.v.) bolus at 3-week intervals according to a balanced cross-over design. Unchanged DX and epiDX plasma levels followed a triexponential decay. Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h). According to a model-independent analysis, the different plasma disposition kinetics of the two compounds appears to be related to a higher plasma clearance (PlCl) and to a lower mean residence time (MRT) of epiDX (PlCl: 75.0 l/h, range: 35.6-133.4 l/h; MRT: 31.6 h, range: 7.0-41.5 h;) compared to DX (PlCl: 56.8 l/h, range: 24.4-119.5; MRT: 45.6 h, range: 26.0-83.1 h). No statistically significant differences could be detected for the volume of distribution at steady state (Vss) (epiDX, 31.8 l/kg; DX, 33.3 l/kg). Metabolites common to both compounds were detected in plasma: the 13-dihydro derivatives doxorubicinol (DXol) and epirubicinol (epiDXol), together with minor amounts of four aglycones (7-deoxy adriamycinone, adriamycinone, 7-deoxy 13-dihydro adriamycinone, and 13-dihydro adriamycinone). Following epiDX administration, two additional major metabolites were detected: the glucuronic acid conjugates of epiDX (4'-O-beta-D-glucuronyl-4'-epiDX) and epiDXol (4'-O-beta-D-glucuronyl 13-dihydro-4'-epiDX). This additional detoxication route appears to account for the more efficient and faster elimination of epiDX than of DX. In the urine collected in the 6 days after treatment, 12.2% of the DX and 11.9% of the epiDX dose was excreted as unchanged drug and fluorescent metabolites. A comparable renal clearance was calculated for DX (4.7 l/h, range 1.4-7.0 l/h) and epiDX (4.4 l/h, range 1.7-7.0 l/h). One patient with hepatic metastases and abnormal bilirubin serum level had percutaneous biliary drainage because of extrahepatic obstruction. The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h). This patient's biliary excretion accounted for 35.4% of the epiDX dose and 18.2% of the DX dose.
Collapse
|
77
|
Pannuti F, Coppi G, Borella F, Martoni A, Urbano L, Melotti B. Pharmacokinetics of PTT-119 in man. CHEMIOTERAPIA : INTERNATIONAL JOURNAL OF THE MEDITERRANEAN SOCIETY OF CHEMOTHERAPY 1988; 7:113-6. [PMID: 3396115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The pharmacokinetics of PTT-119, a new alkylating agent, was studied in 8 advanced cancer patients. PTT-119 disappeared rapidly from plasma after administration at a dose of 3 mg/kg by i.v. bolus injection. The HPLC method shows plasma levels of m-bis (dichloroethyl)amino-phenyl-L-alanine which is the major metabolite of PPT-119. Elimination of the drug from plasma can be described by a one-compartment model. Mean values of 77.8 min for the half-life, 510.8 ml/min for the total plasma clearance and 0.69 l/kg for the volume of distribution were found.
Collapse
|
78
|
Pannuti F, Martoni A, Cilenti G, Camaggi CM, Fruet F. Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY 1988; 24:423-9. [PMID: 2968262 DOI: 10.1016/s0277-5379(98)90012-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The present paper concerns two multicenter studies on adjuvant therapy with medroxyprogesterone acetate (MAP) for operable N+ breast cancer. The patients entered the study between April 1979 and March 1986. One hundred and fifty-one premenopausal patients were randomly assigned to receive either polychemotherapy (CMF) or CMF + MAP. One hundred and thirty-eight postmenopausal patients were randomized to receive either MAP h.d. or no treatment. CMF was administered according the following schedule: cyclophosphamide mg 100/ms p.o. 1-4 days; methotrexate mg 40/ms i.v. and fluorouracil mg 600/ms i.v. 1st and 8th days. The cycle was repeated six times every 28 days. MAP was administered at 1000 mg X 2/daily p.o. for 30 days and afterwards 500 mg X 2/daily for 5 months. In the premenopausal study after a median follow-up of 36 months no difference was observed in the incidence of recurrence, site of recurrence, actuarial 5-year disease-free survival (DFS) or overall survival (OS). In the postmenopausal study a statistically significant lower number of recurrences was observed in MAP-treatment patients after a median follow-up of 37 months. The effect of MAP was limited to patients with less than or equal to 3 metastatic axillary lymph nodes. In addition, there are suggestions that only patients with ER+ tumors draw some advantage from the treatment. On the other hand, no difference exists in the OS. The treatments were substantially well tolerated. The MAP + CMF regimen induces lower vomiting compared to the CMF alone. The most frequent MAP side-effects were vaginal spotting (16%) and tremors (12%). We conclude that MAP h.d., like tamoxifen and aminoglutethimide, can improve the DFS of operable N+ breast cancer in postmenopausal patients.
Collapse
|
79
|
Pannuti F, Camaggi CM, Strocchi E. The role of pharmacokinetics in the clinical treatment of metastases. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1988; 233:443-52. [PMID: 2975917 DOI: 10.1007/978-1-4899-5037-6_48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
80
|
Pannuti F, Longhi A, Martoni A, Piana E, Baroni M. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients. CHEMIOTERAPIA : INTERNATIONAL JOURNAL OF THE MEDITERRANEAN SOCIETY OF CHEMOTHERAPY 1987; 6:396-8. [PMID: 2963702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Twenty-six postmenopausal consecutive patients with advanced breast cancer were treated with very high medroxyprogesterone acetate doses (4000 mg/day orally for 30 days and then 3000 mg/day orally until progression or intolerance). The dominant metastatic lesion was bone in 13 patients, soft tissue in 3 patients and viscera in 10 patients (C.I. = V/ST + 0 = 0.62). An objective partial remission was achieved in 16 pts (61%), no change in 8 (31%), progression in 2 (8%). The median duration of objective remission was 7.5+ months with a median survival of 14.5+ months in responders. Toxicity was minor and only two patients discontinued the treatment because of side-effects. These results confirm the utility of medroxyprogesterone acetate at very high doses in these patients and the feasibility of this kind of dose.
Collapse
|
81
|
Pannuti F, Camaggi CM, Strocchi E, Comparsi R. Medroxyprogesterone acetate plasma pharmacokinetics after intravenous administration in rabbits. Cancer Chemother Pharmacol 1987; 19:311-4. [PMID: 2954713 DOI: 10.1007/bf00261479] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Medroxyprogesterone acetate (MAP) plasma pharmacokinetics was followed up in a total of 30 New Zealand rabbits after i.v. administration (0.1, 0.5, and 1.0 mg/kg) of either an aqueous suspension or a homogeneous solution of the drug in dimethylsulphoxide (DMSO). A well-defined triphasic decay of MAP plasma levels was noticeable in the animals treated with DMSO solutions. A delayed concentration peak was often present when aqueous suspensions were used, so if is not feasible to fit the experiment with simple polyexponential equations. Model-independent pharmacokinetic analysis (statistical moment theory) revealed a significant dependence of plasma clearance and mean residence time on the dose administered in both conditions.
Collapse
|
82
|
Lelli G, Casadio M, Giordani S, Giuliotti C, Canova N, Martoni A, Pannuti F. 4'-Epidoxorubicin plus cisplatin as first-line therapy in the treatment of small cell bronchogenic carcinoma. CHEMIOTERAPIA : INTERNATIONAL JOURNAL OF THE MEDITERRANEAN SOCIETY OF CHEMOTHERAPY 1987; 6:134-6. [PMID: 3036379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Twenty-seven patients with small cell bronchogenic carcinoma were treated with a combination of 4'-Epidoxorubicin 60 mg/m2 and cisplatin 50 mg/m2 i.v. every 3-4 weeks. Three patients (11%) had a complete remission (CR), and 12 (44%) had a partial remission (PR) with a 55% overall remission rate. The median duration of response was 36 weeks (range 11-256+). No severe bone marrow depression was noted. The other side effects were of mild grade. Because of the "minimal aggressiveness" of this combination for the patients, the results obtained in this preliminary phase can probably be improved by the integration of other drugs in the scheme.
Collapse
|
83
|
Pannuti F, Martoni A, Camaggi C. Map at high doses: Positive and undesirable side-effects. ACTA ACUST UNITED AC 1987. [DOI: 10.1016/0022-4731(87)91651-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
84
|
Martoni A, Pacciarini MA, Piana E, Pannuti F. A pilot study of oral idarubicin in metastatic melanoma. CHEMIOTERAPIA : INTERNATIONAL JOURNAL OF THE MEDITERRANEAN SOCIETY OF CHEMOTHERAPY 1986; 5:414-5. [PMID: 3467876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Seventeen patients with disseminated melanoma were treated with Idarubicin (IDA) at the dose of 15 mg/m2 daily for 3 consecutive days every 4 weeks by oral route. One complete remission and one partial remission were achieved (remission rate: 12%). The treatment was well tolerated. We conclude that oral IDA may be considered for a pilot trial in a regimen of combination therapy in patients with metastatic melanoma.
Collapse
|
85
|
Pannuti F, Camaggi CM, Strocchi E, Comparsi R, Rossi AP, Angelelli B, Franchini A. Intrahepatic arterial administration of 4'epidoxorubicin (epirubicin) in advanced cancer patients. A pharmacokinetic study. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY 1986; 22:1309-14. [PMID: 3470178 DOI: 10.1016/0277-5379(86)90138-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Epirubicin (epiDX) pharmacokinetics was followed in 10 advanced cancer patients with hepatic metastases from colorectal carcinoma or primary liver tumor after single bolus administration (20-40 mg) in the hepatic artery, through a surgically implanted catheter and subcutaneous access port. EpiDX plasma and whole blood concentrations follow a triphasic decay qualitatively similar to that observed after IV administration. Blood levels are consistently higher than plasma levels. Plasma clearance (nine patients, mean: 93.4 l/hr; range: 69.3-129.5 l/hr) is higher than the corresponding parameter determined in patients with hepatic metastases after intravenous therapy. The remaining patient is characterised by an abnormally low plasma clearance (13.6 l/hr), due to a hepato-pulmonary shunt. The subjects in this study were exposed to very low drug concentrations, and therefore experienced no relevant adverse side-effects.
Collapse
|
86
|
Camaggi CM, Strocchi E, Comparsi R, Testoni F, Angelelli B, Pannuti F. Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. Cancer Chemother Pharmacol 1986; 18:47-50. [PMID: 3463434 DOI: 10.1007/bf00253063] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Plasma pharmacokinetics and biliary and urinary excretion of the new doxorubicin analogue, epirubicin, have been studied in three patients with extrahepatic obstruction and percutaneous biliary drainage. At variance with the reported observations concerning doxorubicin metabolism, conjugation of epirubicin and 13-dihydroepirubicin with glucuronic acid takes place, and corresponding amounts of 4'-o-beta-D-glucuronyl-4'-epidoxorubicin and 4'-o-beta-D-glucuronyl-13-dihydro-4'-epidoxorubicin can be found in the bile and urine. The total amount of unaltered drug and metabolites excreted in the bile in the first 4 days after treatment accounts for the 37%, 27%, and 40% of the administered dose; urinary excretion accounts for 19%, 16%, and 26%. Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h). The relevance of the biliary disposition of epirubicin suggest prudent dose reduction in patients with impaired biliary drainage.
Collapse
|
87
|
Pannuti F, Strocchi E, Longhi A, Comparsi R, Camaggi CM. Medroxyprogesterone acetate plasma levels after a single oral administration of two drug formulations. CHEMIOTERAPIA : INTERNATIONAL JOURNAL OF THE MEDITERRANEAN SOCIETY OF CHEMOTHERAPY 1986; 5:237-9. [PMID: 2945648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
A comparison has been made between the absorption of oral medroxyprogesterone acetate (MPA) in an aqueous suspension preparation and in syrup form. Plasma drug profiles were measured after a single administration of the two formulations in 17 advanced cancer patients. On average the standard form (aqueous suspension) gave peak levels which were lower than the syrup mixture. However, the wide intersubject spread in MPA plasma levels observed in both groups did not allow any statistical significance to be assigned to this difference.
Collapse
|
88
|
Lelli G, Casadio M, Giuliotti C, Giordani S, Martoni A, Strocchi E, Pannuti F. Phase II studies on weekly cisplatinum plus epirubicin or etoposide in the treatment of advanced non-small cell bronchogenic carcinoma. CHEMIOTERAPIA : INTERNATIONAL JOURNAL OF THE MEDITERRANEAN SOCIETY OF CHEMOTHERAPY 1986; 5:228-31. [PMID: 3021346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Thirty-six patients with advanced non-small cell bronchogenic carcinoma were divided in 2 groups for treatment with two different platinum-based combination therapy regimens. All 16 patients who received the weekly administered combination of 10 mg/m2 cisplatin (CDDP) plus 10 mg/m2 epirubicin (4EPIDX) experienced no clinical response. Among the 20 patients who received the combination CDDP (10 mg/m2) plus etoposide (VP16, 60 mg/m2) weekly, 4 of them (20%) showed partial remission (PR). The side effects of both combinations were of mild grade. Further study is needed to verify the effectiveness of the weekly combination of CDDP and VP16 by comparing the above regimen with the "standard" intermittent doses.
Collapse
|
89
|
Pannuti F, Vancini B, Comparsi R, Strocchi E, Camaggi CM. Rectal administration of medroxyprogesterone acetate in cancer patients: a pharmacokinetic study. CANCER TREATMENT REPORTS 1986; 70:937-8. [PMID: 2941143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
90
|
Pannuti F, Camaggi CM, Strocchi E, Martoni A. MPA at high doses in advanced breast cancer: a statistical evaluation. CHEMIOTERAPIA : INTERNATIONAL JOURNAL OF THE MEDITERRANEAN SOCIETY OF CHEMOTHERAPY 1986; 5:159-63. [PMID: 2941172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
A computerized, retrospective analysis of clinical and pharmacokinetic data relative to 380 cancer patients under medroxyprogesterone acetate (MPA) therapy has been carried out. A bioavailability:objective- response correlation was found only for mammary cancer patients with visceral metastases and a pain-control effect was observed in advanced cancer patients when MPA plasma levels were higher than 150-200 ng/ml. Discriminant analysis of the known prognostic factors for breast cancer indicates that receptorial status, site of predominant metastases, basal alkaline phosphatase and free interval are good predictors for possible clinical response, while the behavior of prolactin and previous treatments are predictors for non-response. There is no improvement in the efficacy of prediction in combining more than one prognostic factor.
Collapse
|
91
|
Pannuti F, Camaggi CM, Strocchi E, Comparsi R, Angelelli B, Pacciarini MA. Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. Cancer Chemother Pharmacol 1986; 16:295-9. [PMID: 3457647 DOI: 10.1007/bf00293996] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Data relating to 4-demethoxydaunorubicin (DMDR) pharmacokinetics after oral administration (10-15 mg/m2 per day for 3 days) were collected in a total of 12 patients with advanced breast cancer and melanoma. Drug absorption took place in the first 2-4 h after administration. Plasma levels of the reduced metabolite DMDRol were higher than those of the parent compound: Peak levels were 4-10 ng/ml for DMDR and 15-40 ng/ml for DMDRol. The dose-corrected area under the time-concentration curve (AUC) was consequently higher for DMDRol (12.3-74.7, mean 32.6 vs 2.4-7.4, mean 4.6 ng/ml.mg for DMDR). Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol. Drug and the reduced metabolite accumulated in the blood cells; the ratio of AUC (blood) to AUC (plasma) was 1.40-3.75 (mean 2.80) for DMDR and 1.29-3.50 (mean 2.16) for DMDRol. The biliary excretion of the drug and of the fluorescent metabolites was studied in two additional patients with extrahepatic obstruction and percutaneous biliary drainage. In the first 7 days of therapy, biliary excretion (DMDR + DMDRol) accounted for 3.7%-4% of the administered dose. In contrast to our observations with doxorubicin and epirubicin, urinary excretion seems very likely to be more important for this drug than biliary excretion. In these patients urinary excretions were 2.2, 2.9 times (for DMDR) and 1.2, 3.4 times (for DMDRol) the biliary excretion.
Collapse
|
92
|
Martoni A, Pacciarini MA, Pannuti F. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY 1985; 21:803-6. [PMID: 3862582 DOI: 10.1016/0277-5379(85)90218-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The new anthracycline-analogue 4-demethoxydaunorubicin (4-DMDR) was administered orally at the dose of 15 mg/m2 daily for three consecutive days and repeated every 21-28 days on 29 patients with advanced pretreated breast cancer. A partial remission was observed in 7/25 evaluable patients (28%) for a median duration of 7 months. Side-effects include leukopenia in 93% of the patients (less than 1000 WBC/mm3 in 7%), nausea in 41%, mild vomiting in 17%, diarrhea in 10% and alopecia in 10% of the patients. No definitive conclusion is possible regarding cardiotoxicity. Only mild changes in ECG were observed in two patients. This study shows that 4-DMDR administered orally is well tolerated in the majority of patients and has antitumor activity in advanced breast cancer.
Collapse
|
93
|
Garofalo FA, Messina S, De Santis P, Lalanne MG, Nanni G, Tomaselli VC, Strocchi E, Pannuti F. Contributo Alla Conoscenza Della Farmacocinetica Del Medrossiprogesterone Acetato Ad Alte Dosi Nel Trattamento Del Cancro Del Rene. Urologia 1985. [DOI: 10.1177/039156038505200309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
94
|
Pannuti F, Ferrari P, Fruet F, Marrano D, Piana E. [New trends in hormone therapy]. Pathologica 1985; 77:347-8. [PMID: 3831885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
|
95
|
Pannuti F, Martoni A, Farabegoli G, Piana E. Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments. CHEMIOTERAPIA : INTERNATIONAL JOURNAL OF THE MEDITERRANEAN SOCIETY OF CHEMOTHERAPY 1985; 4:127-34. [PMID: 3159487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Seventy postmenopausal patients with advanced breast cancer, the majority not having been pretreated, underwent a hormonal profile study (LH, FSH, PRL, E2, testosterone, TSH, T3, T4, FT3, FT4 serum levels) by RIA standard methods. The result was that these patients had the same mean hormonal profile of normal controls. The hormonal profile was studied in 66 patients before and after one month of treatment with medroxyprogesterone acetate at high doses (MAP h.d.) (45 patients), tamoxifen (TAM) (10 pts.) and MAP h.d. + TAM + bromocriptine (MTB) (11 pts.). No significant difference in the pre-treatment hormonal profile was observed in either patients who responded to the subsequent treatment or in those who did not. MAP h.d. induced a marked inhibition of gonadotropins, E2, testosterone, T3, T4 while PRL, TSH and FT3 remained unchanged and FT4 increased. TAM induced a decrease of gonadotropins and T4 while all the other hormones remained unchanged. MTB induced the same effects of MAP h.d. as well as a decrease of PRL serum levels. All hormonal variations except PRL occurred independently of the clinical response. A particular behaviour of PRL was evident after one month of treatment with MAP h.d. and TAM: patients who did not respond had a statistically significant increase of PRL serum levels while in responders the PRL serum levels decreased or remained unchanged. Specifically 24 out of 28 (86%) patients with an increase greater than 20% of the PRL levels were non-responders.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
96
|
Camaggi CM, Strocchi E, Canova N, Costanti B, Pannuti F. Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses. Cancer Chemother Pharmacol 1985; 14:229-31. [PMID: 3158448 DOI: 10.1007/bf00258121] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Plasma levels of medroxyprogesterone acetate (MAP), tamoxifen (TMX) and its major metabolites, 4-hydroxy TMX and desmethyl TMX, were determined in five patients with advanced breast cancer following simultaneous MAP (2,000 mg/day) and TMX (20 mg/day) oral therapy. The interindividual variance in MAP plasma levels was wide; the mean plasma levels of both drugs were nearly identical, despite the large difference in the administered doses.
Collapse
|
97
|
Camaggi CM, Strocchi E, Costanti B, Beghelli P, Ferrari P, Pannuti F. Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer. Cancer Chemother Pharmacol 1985; 14:232-4. [PMID: 3158449 DOI: 10.1007/bf00258122] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Administration of medroxyprogesterone acetate IP in advanced cancer with peritoneal metastases and ascitic effusion generates considerably higher drug plasma levels than those observed after PO or IM treatment. Comparison of areas under the time-concentration curves (AUC) with reference to the three administration routes indicates that after oral administration only 0.2%-17.4% (mean 5.7%; SD 3.77; 40 patients) of the administered dose is absorbed; after IM treatment a daily absorption of 0.7%-7.7% (mean 2.5%; SD 1.66; 30 patients) of the administered dose per injection site was computed.
Collapse
|
98
|
Periti P, della Cuna GR, Pannuti F, Mazzei T, Preti P, Martoni A, Mini E. First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer. Invest New Drugs 1985; 3:167-71. [PMID: 4019120 DOI: 10.1007/bf00174165] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
In this study, 30 evaluable patients with advanced carcinoma of the breast were treated with cyclophosphamide 600 mg/m2 i.v. followed one day later with mitoxantrone (Novantrone; dihydroxyanthracenedione) 16 mg/m2 i.v. Drug treatment was repeated every 3-4 weeks, for a maximum of 12 cycles. The overall response rate was 43%; five of 30 patients (16%) attained a complete remission, and eight of 30 (27%) had a partial remission. Median response duration was 12+ months. The greater number of responses was seen in skin and soft tissues. Hematologic toxicity was limiting with 75% of patients experiencing substantial-severe leukopenia. Clinically evident heart failure developed in one patient; in three other patients there was minor-moderate alteration of cardiac function during mitoxantrone-cyclophosphamide therapy. Based on these data, it is believed that this regimen may provide significant long-lasting palliation in patients with advanced breast cancer.
Collapse
|
99
|
Pannuti F, Martoni A, Lelli G, Camaggi CM, Strocchi E, Fruet F. [New anthracyclines in the treatment of solid tumors in the advanced stage]. GIORNALE ITALIANO DI CHEMIOTERAPIA 1985; 32:49-56. [PMID: 3868636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
100
|
Strocchi E, Camaggi CM, Pannuti F. [Pharmacokinetics and metabolism of epirubicin in cancer patients in an advanced stage]. GIORNALE ITALIANO DI CHEMIOTERAPIA 1985; 32:13-20. [PMID: 3868635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|